UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 47

Sortiert nach

Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis

Thrombosis and haemostasis, 2015-07, Vol.113 (4), p.719

2015

Volltextzugriff (PDF)

Single-Dose Pharmacokinetics and Metabolism of the Oral Decongestant Phenylephrine HCl in Children and Adolescents

Pulmonary therapy, 2023-03, Vol.9 (1), p.139-150

2023

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa

Clinical pharmacokinetics, 2016-06, Vol.55 (6), p.641-655

2016

Volltextzugriff (PDF)

Comparison of efficacy from two different dosing regimens of bortezomib: an exposure–response analysis

British journal of haematology, 2020-06, Vol.189 (5), p.860-868

2020

Volltextzugriff (PDF)

PET Study Examining Pharmacokinetics, Detection and Likeability, and Dopamine Transporter Receptor Occupancy of Short- and Long-Acting Oral Methylphenidate

The American journal of psychiatry, 2006-03, Vol.163 (3), p.387-395

2006

Volltextzugriff (PDF)

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

British journal of clinical pharmacology, 2016-12, Vol.82 (6), p.1591-1600

2016

Volltextzugriff (PDF)

Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations

The AAPS journal, 2018-05, Vol.20 (3), p.46-46, Article 46

2018

Volltextzugriff (PDF)

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study

British journal of haematology, 2021-03, Vol.192 (5), p.869-878

2021

Volltextzugriff (PDF)

Scientific diligence for oncology drugs: a pharmacology, translational medicine and clinical perspective

Drug discovery today, 2020-10, Vol.25 (10), p.1855-1864

2020

Volltextzugriff (PDF)

Comparison of a transdermal contraceptive patch with a newly sourced adhesive component versus EVRA patch: A double-blind, randomized, bioequivalence and adhesion study in healthy women

Contraception (Stoneham), 2020-04, Vol.101 (4), p.276-282

2020

Volltextzugriff (PDF)

Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule

Journal of clinical pharmacology, 2015-11, Vol.55 (11), p.1286-1292

2015

Volltextzugriff (PDF)

Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White Paper

Clinical pharmacology and therapeutics, 2024-07

2024

Volltextzugriff (PDF)

Population Pharmacokinetic Analysis of Decitabine in Pediatric Patients With Acute Myeloid Leukemia

Journal of clinical pharmacology, 2019-05, Vol.59 (5), p.668-676

2019

Volltextzugriff (PDF)

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients

Journal of clinical pharmacology, 2021-05, Vol.61 (5), p.614-627

2021

Volltextzugriff (PDF)

The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban

Thrombosis research, 2015-10, Vol.136 (4), p.825-831

2015

Volltextzugriff (PDF)

Phase 1–2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia

British journal of haematology, 2019-08, Vol.186 (3), p.e7-e11

2019

Volltextzugriff (PDF)

Inclusion of Placebos and Blinding for Ascending Dose First‐in‐Human Studies and Other Underpowered Phase 1 Studies has not been Justified and on Balance is Not Useful

Basic & clinical pharmacology & toxicology, 2015-07, Vol.117 (1), p.44-51

2015

Volltextzugriff (PDF)

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

Prostate cancer and prostatic diseases, 2022-02, Vol.25 (2), p.219-228

2022

Volltextzugriff (PDF)

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

Annals of hematology, 2021-04, Vol.100 (4), p.1065-1077

2021

Volltextzugriff (PDF)

Response of authors to Ganju and Dias’ comments on ‘Inclusion of Placebos and Blinding for Ascending Dose First‐in‐Human Studies and Other Underpowered Phase 1 Studies Has Not Been Justified and on Balance is Not Useful’ by D. A. Parasrampuria and L. Z. Benet

Basic & clinical pharmacology & toxicology, 2015-12, Vol.117 (6), p.367-367

2015

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects

Clinical drug investigation, 2016-02, Vol.36 (2), p.127-136

2016

Volltextzugriff (PDF)

Do formulation differences alter abuse liability of methylphenidate? : A placebo-controlled, randomized, double-blind, crossover study in recreational drug users

Journal of clinical psychopharmacology, 2007-10, Vol.27 (5), p.459-467

2007

Volltextzugriff (PDF)

Assessment of Pharmacokinetics and Pharmacodynamic Effects Related to Abuse Potential of a Unique Oral Osmotic-Controlled Extended-Release Methylphenidate Formulation in Humans

Journal of clinical pharmacology, 2007-12, Vol.47 (12), p.1476-1488

2007

Volltextzugriff (PDF)

Effect of Calcineurin Inhibitor Therapy on P-gp Expression and Function in Lymphocytes of Renal Transplant Patients: A Preliminary Evaluation

Journal of clinical pharmacology, 2002-03, Vol.42 (3), p.304-311

2002

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(30)

Publikationsform

Sprache

Englisch
(47)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis

Single-Dose Pharmacokinetics and Metabolism of the Oral Decongestant Phenylephrine HCl in Children and Adolescents

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa

Comparison of efficacy from two different dosing regimens of bortezomib: an exposure–response analysis

PET Study Examining Pharmacokinetics, Detection and Likeability, and Dopamine Transporter Receptor Occupancy of Short- and Long-Acting Oral Methylphenidate

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study

Scientific diligence for oncology drugs: a pharmacology, translational medicine and clinical perspective

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

Comparison of a transdermal contraceptive patch with a newly sourced adhesive component versus EVRA patch: A double-blind, randomized, bioequivalence and adhesion study in healthy women

Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule

Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White Paper

Population Pharmacokinetic Analysis of Decitabine in Pediatric Patients With Acute Myeloid Leukemia

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients

The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban

Phase 1–2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia

Inclusion of Placebos and Blinding for Ascending Dose First‐in‐Human Studies and Other Underpowered Phase 1 Studies has not been Justified and on Balance is Not Useful

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

Response of authors to Ganju and Dias’ comments on ‘Inclusion of Placebos and Blinding for Ascending Dose First‐in‐Human Studies and Other Underpowered Phase 1 Studies Has Not Been Justified and on Balance is Not Useful’ by D. A. Parasrampuria and L. Z. Benet

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects

Do formulation differences alter abuse liability of methylphenidate? : A placebo-controlled, randomized, double-blind, crossover study in recreational drug users

Assessment of Pharmacokinetics and Pharmacodynamic Effects Related to Abuse Potential of a Unique Oral Osmotic-Controlled Extended-Release Methylphenidate Formulation in Humans

Effect of Calcineurin Inhibitor Therapy on P-gp Expression and Function in Lymphocytes of Renal Transplant Patients: A Preliminary Evaluation

Suchergebnisse filtern